New Drug Doubles Survival Time for Pancreatic Cancer Patients

A new drug, daraxonrasib, has doubled survival time for pancreatic cancer patients in a recent clinical trial, showcasing significant advancements in cancer treatment. Other breakthroughs presented at the American Society of Clinical Oncology meeting include a jab for head and neck cancers and an immunotherapy for bladder cancer. These developments highlight ongoing progress in cancer research, often marked by incremental victories rather than definitive cures.

Read the full story at The Guardian AU→